The Drug Enforcement Administration (DEA) announced that COVID-19 telemedicine flexibilities for controlled substances will be temporarily extended for six months – through November 11, 2023.

For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding prescription of controlled medications established during the COVID-19 PHE will be extended for one year – through November 11, 2024.